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1. Introduction 
 
1.1  Mesenchymal stem cells are multipotent stem cells with 
mesodermal origin 
Stem cells are specialized cells with the capacity of self-renewal and differentiation in many 
cell lineages. They can be divided in three main categories: embryonic stem cells (ESC) 
(Thomson et al., 1998), induced pluripotent stem cells (iPSC) (Takahashi and Yamanaka, 
2006) and adult stem cells (Maximow, 1909). 
Mesenchymal Stem (or Stromal) Cells (MSC) are adult stem cells derived from the 
mesodermal layer. In the past, MSC were mistakenly considered to be able to repair and 
regenerate almost all tissues (Prockop, 1997). Actually, it is known that they are 
multipotent cells, belonging to the group of adult stem cells, that can generate only 
mesodermal lineage cells, such as adipocytes, chondrocytes and osteocytes (Nardi and 
da Silva Meirelles, 2006), while maintaining their potential ectodermal (Petersen et al., 
1999) and neuroectodermal (Beyth et al., 2005) differentiation. 
MSC were first isolated from bone marrow (Friedenstein et al., 1974), but have been 
reported in numerous adult organs and tissues (da Silva Meirelles et al., 2006), including 
adipose tissue, umbilical cord, amniotic fluid and endometrium (Ullah et al., 2015).  
Although there are no known markers specific for MSC, a cell is defined as mesenchymal 
stem if it exhibits adhesion properties in vitro, has a fibroblast-like morphology (Hematti, 
2012), is recognized by the monoclonal antibody STRO-1 and is phenotypically identified 
by expression of surface stromal markers, including Cluster of Differentiation 44 (CD44), 
CD71, CD73, CD90, CD105, CD271 and Ganglioside GD2, concomitantly with the lack of 
expression of hematopoietic markers CD11b, CD14, CD19, CD34, CD45, CD79a, Major 
Histocompatibility Complex class II (MHCII), or costimulatory molecules CD80, CD86 and 
CD40 (Dominici et al., 2006; Chamberlain et al., 2007; Horwitz et al., 2005). 
 
1.2  MSC have an anti-inflammatory effect on immune cells in vitro 
In 2002, the demonstration that bone marrow-derived MSC were able to inhibit T-cell 
proliferation in vitro (Di Nicola et al., 2002; Bartholomew et al., 2002) set the basis for the 
studies of the significant therapeutic plasticity that characterizes this cell population. 
Indeed, MSC have the capacity to modulate effector functions of different cells of both 
innate and adaptive immunity (Lovato et al., 2013), through a direct or indirect mechanism. 
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1.2.1 MSC modulate the effector functions of T and B cells in vitro 
The direct inhibition of T cells by MSC depends on the release of soluble factors, including 
indoleamine 2,3-dioxygenase (IDO), prostaglandin 2 (PGE-2), interleukin 10 (IL-10), 
transforming growth factor β (TGF-β), through which MSC are able to make T cells anergic 
(Benvenuto et al., 2007; Glennie et al., 2005; Ghannam et al., 2010) or to skew their 
phenotype to a regulatory one (Treg) (Melief et al., 2013). A recent study showed that MSC 
promote the formation of CD4+CD25+ Treg cells, directly through production of TGF-β1, or 
indirectly through release of chemokine (C-C motif) ligand 18 (CCL18), which induces 
monocytes to acquire an anti-inflammatory phenotype and to promote Treg development 
(Melief et al., 2013).  
While some studies showed that MSC have a direct inhibitory effect on B-cell proliferation, 
maturation and antibody release in vitro (Corcione et al., 2006), others demonstrated that 
MSC induce proliferation and differentiation of purified B cells (Traggiai et al., 2008). Such 
controversy was resolved with the demonstration that MSC need T-cell signals for being 
able to modulate B cells effects (Rosado et al., 2015). When MSC are stimulated with IFN-
γ, released by effector T cells, they create more interactions with B cells through binding 
between programmed cell death 1 (PD-1), expressed on MSC, and its ligand (PDL-1), 
expressed on B cells. The cross-talk between MSC and B cells induces inhibition of B-cell 
receptor-mediated activation of follicular and marginal zone B cells isolated from lupus 
mice (Schena et al., 2010). 
MSC suppress B-cell maturation independently of cell contact and the soluble factors 
involved are still unknown, but the pathway of B lymphocyte–induced maturation protein-
1 (Blimp-1), a transcriptional factor that regulates B-cell differentiation, is dysregulated 
(Asari et al., 2009). Asari and co-workers confirmed that the MSC suppressive activity on 
B cells acts through paracrine mechanisms also in vivo; indeed, administration of MSC-
conditioned medium (MSC-CM), supernatant of MSC culture, in mice results in a decrease 
of IgM and IgG production (Asari et al., 2009). An in vitro study demonstrated that in the 
presence of MSC plasmablast development was decreased, but MSC induced the 
formation of CD19+CD24highCD38high IL-10-secreting B cells, known as regulatory B 
cells (Franquesa et al., 2015). 
MSC have immunomodulatory effects on T and B cells also through indirect mechanisms, 
influencing differentiation and functions of myeloid-derived cells, such as Dendritic cells 
(DC) and macrophages, related to the adaptive immune response. 
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1.2.2 MSC affect the activity of cells of the innate immunity in vitro 
MSC inhibit differentiation of monocytes into immature DC (Nauta et al., 2006; Spaggiari 
et al., 2009). In vitro and in vivo studies showed that MSC impair Toll–like receptor (TLR) 
activation of DC, inhibiting their capacity to present antigen to T cells (Chiesa et al., 2011), 
which results in decreased T-cell proliferation. Cytokine production by activated DC was 
blocked by MSC through release of soluble factors that weaken the activation of the 
mitogen-activated protein kinase (MAPK) cascade of the NF-κB pathway, upregulated 
upon TLR4–induced DC activation (Chiesa et al., 2011).  
Specifically, MSC influence DC to assume a suppressive phenotype through release of 
growth-regulated oncogene (GRO) chemokines (Chen et al., 2013). When DC are 
activated by Gro-γ, they induce T cells to differentiate toward a tolerogenic phenotype, 
characterized by the production of high levels of anti-inflammatory cytokines, such as IL-
10 and IL-4, and reduced levels of pro-inflammatory cytokine expression, such as IL-12 
and IFN-γ (Chen et al., 2013). 
MSC exert their effect on DC not only through paracrine mechanisms: a direct contact 
MSC-DC is required to inhibit formation of active immune synapses by DC with T cells 
(Aldinucci et al., 2010). 
MSC have also been shown to interact with NK cells in vitro (Spaggiari et al., 2006; 
Sotiropoulou et al., 2006; Krampera et al., 2006; Poggi et al., 2005); MSC can block IL-2-
mediated NK cell proliferation (Spaggiari et al., 2006), and effector functions, such as 
cytotoxicity and cytokine secretion (Sotiropoulou et al., 2005; Spaggiari et al., 2008). This 
inhibitory effect of MSC is mediated by released IDO, PGE2, and TGF-β, that induce a 
down-regulation of the expression of specific NK receptors, NKp30, NKp44, and NKG2D 
(Spaggiari et al., 2008). Unfortunately, the underlying mechanisms are yet unknown. 
MSC play a suppressive role also on macrophages through a direct cell-to-cell contact, 
inducing pro-inflammatory macrophages (M1 phenotype) to acquire an anti-inflammatory 
profile (M2 phenotype), but the modulatory mechanism of activated macrophages by MSC 
is still unknown (Siniscalco et al., 2011). When put in co-culture with LPS-activated alveolar 
macrophages (macrophages that acquire a pro-inflammatory phenotype also known as 
M1 macrophages), MSC cause a deregulation in the expression of inflammatory cytokines, 
such as IL-1α and IL-6, resulting in a skewing of M1 macrophages toward an anti-
inflammatory phenotype (M2 macrophages) and an increase in the expression of anti-
inflammatory factors (Jin et al., 2013). Dayan et al. observed that pro-inflammatory 
macrophages were induced to assume an alternative activated profile by the 
overexpression of IL-10 by MSC (Dayan et al., 2011). Moreover, MSC induce 
macrophages to acquire a regulatory phenotype, characterized by an increase in 
expression of IL-10 and reduced levels of molecules inducing T-cell activation, such as 
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TNF-α, IL-12, and co-stimulatory molecule CD86 (Maggini et al., 2010). A recent study in 
vitro demonstrated that human MSC modulate both human and mouse macrophage 
activity through the inhibition of NLRP3 inflammasome activation in LPS or ATP-activated 
macrophages (Oh et al., 2014). Kim and Hematti confirmed the capacity of MSC to 
promote an alternative activation of macrophages in vitro, as demonstrated by the 
expression of high levels of IL-6 and CD206, typical markers of alternatively activated 
macrophages, and IL-10, together with low levels of TNF-α and IL-12, specific markers of 
classical macrophage activation, in macrophages exposed to MSC (Kim and Hematti, 
2009). This shift in phenotype was accompanied by an improved phagocytic activity of 
macrophages (Kim and Hematti, 2009). 
As a consequence of the modulatory/suppressive effect of MSC on the peripheral immune 
cells in vitro, we postulated that MSC could affect also microglial cells, which represent the 
resident macrophages in the central nervous system (CNS). 
 
1.3  Microglia are resident macrophages of the CNS 
In 1920, Pío del Río-Hortega discovered a new type of cells belonging to neuroglia 
population in the CNS, microglia (Tremblay et al., 2015).  
Even if they are considered one of the four main cellular type of CNS, microglia do not 
arise from the same precursors as neurons, astrocytes and oligodendrocytes, but they are 
macrophages resident in the CNS originating from myeloid progenitor cells and sharing 
various markers with dendritic cells, monocytes and peripheral macrophages, such as 
CD11b, F4/80 (also known as EMR1 or Ly71) and CD45 (Prinz et al., 2011). 
Microglial cells originate in the yolk sac during early hematopoiesis (Ginhoux et al., 2010). 
Later the hematopoietic precursors migrate to the brain and proliferate in situ (Alliot et al., 
1999). After their migration in the neural tissue, the cells resettle stably in the CNS and 
undergo self-renewal until the adult age (Ginhoux et al., 2010; Greter and Merard, 2013). 
Microglia are ubiquitously present in brain and spinal cord and it was estimated that they 
represent about 10% of all cells found within the CNS (Lawson et al., 1992). 
At the beginning, microglia were considered as a population of inactivated and quiescent 
cells (Davalos et al., 2005; Nimmerjahn et al., 2005), but through two-photon microscopy, 
it was observed that also in absence of damage, microglia are surprisingly dynamic 
(Schwartz et al., 2006), playing an important role in the maintenance of tissue homeostasis 
and in defense mechanisms for the CNS against exogenous and endogenous threats; 
indeed, they are able to eliminate dead cells and harmful debris through phagocytosis and 
to produce cytokines and growth factors (Aloisi et al., 2000), having a beneficial role for 
the CNS. 
 7 
 
Microglial cells play a relevant role in neuroinflammation, including tissue repair and 
regeneration, immunosuppression and cytotoxicity; indeed, they are able to acquire 
different states or phenotypes of activation (Chhor et al., 2013).  
 
1.3.1 Microglia can assume different phenotypes of activation on the basis of 
the signals received 
In a healthy CNS, microglia assume a surveillance phenotype, defined as “resting”, 
characterized by a slow turnover rate, a low expression of functional markers, such as 
MHCII and CD45 (Lynch, 2009), and highly branched and very mobile processes which 
contact neurons and glial cells, while the soma stays fixed and stationary (Kalla et al., 
2001; Davalos et al., 2005; Nimmerjahn et al., 2005). As soon as they detect an event that 
determines the loss of homeostasis or which can lead to tissue damage, such as the 
presence of some extraneous matter, damaged or apoptotic cells, DNA fragments, or 
plaques, microglial cells change their morphological, molecular and functional states, 
ranging from a resting to an ameboid intermediate form with short and thick processes to 
acquire a more active profile (Aloisi, 2001; Chhor et al., 2013) characterized by a bigger, 
granular soma with cytoplasmic inclusions and shorter cellular processes (Frommann et 
al., 1878; Colton and Wilcock, 2010). Furthermore, microglial cells become mobile and 
actively move following chemotactic gradients, causing a cellular thickening in the 
damaging site (Kettenmann et al., 2011). Local microglial density also greatly increases 
due to an intense proliferative activity, in order to offer a more efficient defense mechanism 
(Kettenmann et al., 2011). But when they are excessively and chronically activated, 
microglia lose their protective role and assume a neuroinflammatory, deleterious, 
phenotype. 
The microglia activation process is characterized by the induction of expression or 
rearrangement of surface molecules that mediate cell-cell and cell-matrix interactions, by 
changes in intracellular enzyme activity, as well as by the release of a series of factors 
with pro-inflammatory and immunomodulatory effects (Kettenmann et al., 2011). 
The distinction of activated microglia phenotypes is based on the expression of different 
molecular markers; expression of pro-inflammatory receptors or cytokines with a cytotoxic 
effect distinguish M1-like phenotype or classical activated microglia, whereas anti-
inflammatory receptors or cytokines involved in tissue repair and regeneration are 
overexpressed in an M2-like or alternative microglial activated phenotype (Guedes et al., 
2013; Chhor et al., 2013).  
Microglial cells assume a specific activation state on the basis of the nature, duration, and 
intensity of the received stimulus, and the microenvironment in which they are. Pro-
inflammatory stimuli, such as lipopolysaccharide (LPS), interleukin-1 β (IL-1β) and tumor 
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necrosis factor α (TNF-α), increase genic expression of cytotoxic markers related to M1-
like phenotype, for example cyclooxygenase-2 (Cox-2) and inducible nitric oxide synthase 
(iNOS), and release of factors, such as TNF-α, interleukin-6 (IL-6), and IL-1β (Chhor et al., 
2013). Furthermore, the classical microglial activation is associated with the production of 
reactive oxygen species (ROS) caused by a greater activity of NADPH oxidase. High levels 
of intracellular ROS in microglia amplify their pro-inflammatory cytokines expression 
contributing to microglia neurotoxicity (Block et al., 2007). 
Conversely, the alternative microglia activation is characterized by secretion at high levels 
of anti-inflammatory cytokines, such as IL-4, IL-5 or IL-10, and neurotrophic factors, like 
brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1) and TGF-β 
(Gomes-Leal, 2012; Boche et al., 2013), which lead to a neuroprotective microglial 
phenotype and capacity to inhibit pro-inflammatory response.  
More studies revealed the existence of different states of intermediate activation and 
evidenced that phenotypes M1- and M2-like can overlap, accordingly microglia are able to 
assume a wide spectrum of phenotypes which cannot be simplistically divided in discrete 
categories. 
 
1.3.2 Microglia acquire an activated phenotype in response to the surrounding 
environment 
The CNS milieu is full of molecules that modulate microglial activation; the nature of the 
surrounding tissue directs cells towards a particular phenotype rather than another one.  
Microglial activation is controlled by two classes of signals: off and on signals (Biber et al., 
2007). The off signals are molecules constitutively present in brain environment; their 
absence triggers a microglia activation (Biber et al., 2007). For instance, binding between 
CD200, expressed on neurons, and its receptor (CD200R), expressed on microglia (Hoek 
et al., 2000), represents an off signal; indeed, CD200-CD200R interactions are essential 
to prevent microglial switch from the alternative neuroprotective phenotype to the 
classically activated state, thereby avoiding over-activation of microglia and consequent 
neurotoxicity (Zhang et al., 2011). Another important factor produced by neural cells and 
involved in off signaling is fractalkine (CX3CL1), a C-X-C motif chemokine that acts 
through binding to its specific receptor, CX3CR1, expressed by M2-like microglia, 
preventing neurotoxic activity (Cardona et al., 2006; Lee et al., 2010). Even TGF-β is a 
relevant off signal for modulating microglia activation. Studies demonstrated that in 
presence of TGF-β in the microenvironment, microglia reduce their production of pro-
inflammatory cytokines, while the lack of this factor determines a pathological microglial 
activation, leading to microgliosis and neuronal death (Brionne et al., 2003).The on signals 
appear when cell damage occurs and they act by attracting microglia in the lesion site, 
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through the creation of a chemical gradient. Among the possible chemotactic factors, ATP 
(Kaufmann et al., 2005) triggers the rapid microglial response migration to the lesion site 
(Davalos et al., 2005). This phenomenon involves purinergic receptors (P2), as 
demonstrated by the decrease of microglial chemotactic response in vivo after 
administration of various P2 receptors inhibitors in the cortex (Davalos et al., 2005), or 
through experiments in mice knock-out for metabotropic purinergic receptor P2Y12 
(Haynes et al., 2006), in which motility of microglia is reduced. Even an excessive release 
of neuronal glutamate, associated with neurodegenerative process, acts as an on signal 
for the activation and migration of microglia, presumably through the binding to specific 
ionotropic receptors for glutamate expressed on microglia surface; treatment with α-amino-
3-hydroxy-5-methyl-4-isoxazolone propionate (AMPA), a glutamate agonist, induced 
microglia migration following glutamate concentration gradients (Liu et al., 2009). 
However, the expression of N-methyl-D-aspartate (NMDA) receptor for glutamate remains 
uncertain in microglia. 
The activation of microglia appears to have contradictory consequences, depending on 
inputs and feedback signals from the neural environment. On one hand, M2-like microglia 
activation facilitates the removal of degenerate neurons, inflammatory debris and protein 
aggregates, which are histopathological characteristic of numerous neurodegenerative 
disorders. On the other hand, neurotoxin secretion and pro-inflammatory activities 
associated with microglia M1-like phenotype may aggravate the disease by promoting the 
inflammatory process (Block et al., 2007) and contributing to neurodegeneration. 
Therefore, depending on their state of activation, microglia play different functions in the 
neural tissue (Boche et al., 2013). 
The activation of microglia, whether or not accompanied by microgliosis, occurs practically 
in all diseases of the CNS. Although microglia appear to play a key role in controlling the 
efficiency of the nervous system in healthy subjects, and, in an alternately activated state, 
play a beneficial role in the early stages of the disease, a continued activation is implicated 
in the neurodegeneration process. Recent research has shown an involvement of 
microglial population in neural pathologies, considering it as one of the major causes of 
neuronal malfunction (Derecki et al., 2014). 
 
1.4  MSC can modulate activation of microglia in vitro 
In vitro, MSC are able to modify the activation of microglia both in co-cultures (cultures 
where direct cell-cell contact occurs) and in transwell cultures (cultures in which the two 
different cell types are separated by a porous membrane that avoids a physical interaction 
between the two populations, but allows the cellular communication based on the release 
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of soluble factors). This most likely occurs through inhibition of the activation of mitogen-
activated protein kinase (MAPK) p38, which is essential for microglial activation induced 
by TLR4 (LPS-binding receptor) (Zhou et al., 2009; Pathak et al., 2006). In vitro studies 
from our laboratory have shown that MSC are able to induce a switch of microglia from the 
M1-like phenotype to the classically activated phenotype (M2-like) by releasing CX3CL1, 
recognized by CX3CR1 on microglia. In particular, MSC cause a significant increase of 
expression and release of neuroprotective molecules by activated microglia, while 
significantly decrease the expression and release of various inflammatory factors and 
molecules involved in oxidative stress (Giunti et al., 2012). 
MSC therefore represent an efficient tool through which it might be possible to modulate 
the activation state of microglia, inducing a shift from a neurotoxic, pro-inflammatory 
phenotype to a neuroprotective one. It could partly explain the beneficial effects that are 
associated with MSC therapeutic plasticity in the various experimental models of 
neurological pathologies in which the inflammatory component plays a fundamental role 
(Uccelli and Mancardi, 2010; Uccelli et al., 2011).  
 
1.5  Administration of MSC to mice affected with amyotrophic lateral 
sclerosis-like disease decreases neuroinflammation  
Many neurodegenerative diseases are characterized by a dysregulation of immune 
responses that sustains the neuroinflammation and neural degeneration progress. It has 
been observed that MSC adoptively transferred can migrate in the CNS injured site (Le 
Blon, et al., 2014) and, with their immunomodulation potential on T cells, macrophages, 
and especially microglia, could provide remarkable therapeutic effects (Gordon et al., 
2008). 
Recent evidences suggested the efficacy of MSC-based therapy in treating numerous 
neurodegenerative disease, including amyotrophic lateral sclerosis (ALS; also known as 
Lou Gehrig’s disease) (Hajivalili et al., 2016).  
ALS is an adult-onset neurological disease characterized by degeneration of upper and 
lower motoneurons (MNs) in the motor cortex, brainstem and spinal cord (Bruijn et al., 
2004), causing their progressive loss of function, and eventually leading to death via 
respiratory muscle paralysis (Cozzolino et al., 2008). The etiology of disease is still 
unclear, indeed most ALS cases (90%) are sporadic (SALS), defined as having no obvious 
genetic component (Brown, 1997); only 10% of cases are inherited in a dominant fashion 
(known as familial ALS; FALS). In both SALS and FALS there are similar pathological 
hallmarks, including weakness, atrophy, spasticity (Mulder, 1982) and accumulation of 
phosphorylated neurofilaments in MN axons (Ince et al., 1998). In addition, SALS and 
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FALS show the same overactivation and overproliferation of astrocytes and microglia 
(Uccelli et al., 2012). Twenty percent of ALS are related to mutations in the Cu/Zn 
superoxide dismutase (SOD1) gene. SOD1 is a ubiquitously expressed cytosolic enzyme 
consisting of 153 aminoacids. Binding one zinc and one copper atom, it catalyzes the 
conversion of superoxide radicals into oxygen and hydrogen peroxide (Sea et al., 2015). 
More than 125 mutations on SOD1 gene have been observed but only 114 of them 
provoke disease, inducing a toxic gain-of-function of the enzyme (Turner and Talbot, 2008; 
Ilieva et al., 2009; Rothstein, 2009). 
Among others, an important SOD1 point mutation in which a glycine substitutes the alanine 
at residue 93 (SOD1G93A) is commonly studied in ALS research. The transgenic mice 
expressing many copies of human SOD1G93A were developed by Gurney and 
collaborators, and this animal model shows a progressive adult-onset motor phenotype 
comparable to that seen in patients (Gurney, 1994). In agreement with these data, 
Reaume et al., created mice deficient for SOD1 (SOD1-/-) and observed that those animals 
did not develop motor neuron disease (Reaume et al., 1996). Moreover, transgenic mice 
overexpressing wild-type human SOD1 form were completely healthy (Wong et al., 1995). 
Although the mechanisms underlying the ALS are still unknown, neuroinflammation plays 
an important role in ALS pathogenesis. Microglial activation was observed in the brain and 
spinal cord of ALS patients (Engelhardt and Appel 1990; Henkel et al., 2004; McGeer et 
al., 1991; Troost et al., 1993; Turner et al., 2004) and in the spinal cord of mutant SOD1 
mice (Hall et al., 1998; Henkel et al., 2005; Kriz et al., 2002). Henkel et al. observed a 
previous microglia activation that was followed by loss of MNs (Henkel et al., 2006). Other 
studies confirmed a role for microglia in the pathogenesis of ALS. Forcing activation of 
microglial cells by administrating LPS to SOD1 transgenic mice exacerbated the disease 
(Nguyen et al., 2004), and silencing the expression of CX3CR1 on microglia of mutated 
SOD1 mice accelerated neuronal loss (Cardona et al., 2006). 
In vivo studies in our laboratory have shown that intravenous administration of MSC in 
SOD1G93A mice with overt disease results in a slowdown of pathology progression and an 
improvement of motor function. The beneficial effect is related to the decrease of oxidative 
stress, the inhibition of glutamate-mediated excitotoxicity, but also to a reduction in 
microglial activation and hence of inflammation affecting MNs (Uccelli et al., 2012). 
Immunohistochemical analysis of the spinal cord showed that MSC treatment did not 
induce differences in expression of iNOS markers, insulin-like growth factor 1 (IGF1), 
CX3CR1, and nuclear receptor related 1 protein (Nurr1), but rather a significant down-
regulation of RNA expression for TNF-α and IL-1β pro-inflammatory cytokines in MSC-
treated mice compared to controls (Uccelli et al., 2012). Similarly, Vercelli et al. observed 
that ALS mice transplanted with hMSC into the spinal cord showed a decreased microglial 
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activation and ameliorated motility (Vercelli et al., 2008). Another research group 
systemically administered hMSC in ALS mice and obtained a disease progression 
slowdown with decrease microglial activation and reactivated astrogliosis (Sun et al., 
2014). 
 
1.6  Exosomes mediate intercellular communication transferring 
their content, including microRNAs (miRNA), to target cells 
MSC are among the stem cells most studied for their potential therapeutic capacity, but 
their mode of action in vivo is still unclear. Indeed, administration of MSC intravenously 
results in less than 1% of transplanted MSC reaching the damaged site, the rest being 
trapped in lungs, spleen and liver (Djouad et al., 2003). Accordingly, and on the basis of 
their in vitro effect and, more recently, of the demonstrated therapeutic impact of their 
secretome, their therapeutic effect is likely predominantly attributable to paracrine 
mechanisms (Uccelli et al., 2008). 
A possible paracrine mechanism through which MSC could affect their target cells is the 
release of vesicles, in particular of exosomes (Ludwig and Giebel 2012). Exosomes are 
nanovesicles with a diameter of 40-100 nm of endocytic origin that exhibit a set of 
preserved proteins, including ALIX and CD9, CD63 (Lai et al., 2011). 
Many research groups are studying the capacity of exosomes to mediate paracrine effects 
of the cells that release them. Chen et al. showed that MSC-derived exosomes alter 
production of pro-inflammatory cytokines, TNF-α and IL-1β, on T cells, inducing them to 
secrete anti-inflammatory mediator TGF-β in vitro, and promote a shift to anti-inflammatory 
T cells, with the transformation of T helper type 1 (Th1) into T helper type 2 (Th2) cells and 
the reduced differentiation of T cells to interleukin 17-producing effector T cells (Th17) 
(Chen et al., 2016). Teng et al. observed an anti-inflammatory effect when exosomes 
isolated from MSC conditioned medium are in culture with T cells (Teng et al., 2015). 
Another group demonstrated that MSC affect macrophage activation through microRNAs-
containing exosomes that suppress Toll-like receptor (TLR) expression and inflammatory 
signaling both in vitro and in an in vivo model of lung injury (Phinney et al., 2015). 
Exosomes can affect the fate of the receiving cell through the transfer of their content, 
which includes proteins, mRNA and microRNA (miRNA) into the cellular lumen (Valadi et 
al., 2007).  
MiRNA are small regulatory sequences of non-coding RNA consisting of 20-22 nucleotides 
whose purpose is to regulate gene expression at post-transcriptional level (Bartel, 2004). 
They are transcribed by RNA polymerase II as precursors, called primary miRNA (pri-
miRNA). Pri-miRNA assumes an asymmetric structure, partly single- and partly double-
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stranded with intramolecular interaction. Subsequently, it is processed by RNAse III 
Drosha in the nucleus to form the premature miRNA (pre-miRNA) (Han et al., 2004). The 
pre-miRNA arrives in the cytoplasm of the cell where another RNAse III, Dicer (Bernstein 
et al., 2001), generates the mature form of miRNA (Filipowicz et al., 2008).The mature 
miRNA are mainly expressed in the cytoplasm where they can recognize and target 
specific mRNA, generally preventing their translation or promoting their degradation (Shyu 
et al., 2008). 
The post-transcriptional mechanism mediated by miRNA plays an important role in events 
that determine changes in cell fate, such as differentiation and activation. Several studies 
confirm that miRNA may act as modulators of microglia activation state. One of the first 
described pro-inflammatory miRNA associated with the microglial M1-like phenotype is 
miRNA-155. This particular miRNA is overexpressed in microglial cells in response to 
various pro-inflammatory stimuli, such as LPS, IFN-γ and TNF-α (Cardoso et al., 2012; 
Bala et al., 2011; Wang et al., 2010). In this regard, it has recently been shown that miRNA-
155 decreases the expression of some microglia anti-inflammatory proteins, such as 
suppressor of cytokine signaling 1 (SOCS-1), and causes upregulation of various 
inflammatory mediators characteristic of the M1-like phenotype, including iNOS, IL-6 and 
TNF-α (Cardoso et al., 2012). Interestingly, there is a feedback mechanism that controls 
immune response, indeed the over-expression of miR-155 increases the expression of 
Interferon β (IFN-β), which in turn increases the expression of SOCS-1 and IL-10, two 
major anti-inflammatory mediators (Benveniste et al., 2007; Dalpke et al., 2008). 
Several other miRNA have been directly linked to the alternative activation state of 
microglia. Recently, the role played by miRNA-200b in microglial inflammatory response 
has been analyzed. MiRNA-200b influences various aspects of the microglia inflammatory 
process, particularly reducing pro-inflammatory cytokine secretion, NO production, and 
inducing a neuroprotective activity, and it does this through the modulation of MAPK 
pathway (Jadhav et al., 2014). 
Moreover, it has recently been shown that several miRNA play an important role in the 
control of neuroinflammatory mechanisms. Specifically, miRNA-365 and miRNA-125b are 
over-expressed in the primary microglia obtained from murine model of ALS ALS and they 
contribute to increase TNF-α transcription through IL6-STAT3 pathway repression on 
microglia (Parisi et al., 2013). 
MiRNA-124 is specifically expressed in microglial cells, but not in peripheral monocytes or 
macrophages (Ponomarevet et al., 2011). An overexpression of miRNA-124 in microglia 
induces activated cells to assume a quiescent resting phenotype, characterized by low 
expressions of CD45 and MHCII (Ponomarev et al., 2011). In EAE mice, animal model of 
Multiple Sclerosis (MS), miR-124 is downregulated in M1-like microglia, and its 
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administration deactivates microglia and reduces activation of T cells (Ponomarev et al., 
2011). 
Since miRNA affect the expression of different proteins and the signaling pathways in 
which those proteins are involved, inducing an over-expression or down-regulation of 
specific miRNA could be a useful therapeutic approach. Moreover, it has been shown that 
MSC-derived exosomes are enriched of miRNA with specific pattern, suggesting the 
existence of a finely regulated mechanism of accumulation and transfer of miRNA that 
mirror the cell state (Collino et al., 2010). 
It is well known from the literature that MSC play modulatory roles on innate and adaptive 
immunity mostly through paracrine mechanisms, which include soluble factors or release 
of exosomes. For these reasons MSC are considered a possible alternative therapy for 
neurological disease associated with neuroinflammation, such as ALS. The objects of our 
study were to ascertain whether or not MSC-derived exosomes could affect microglia 
activation through shuttling of specific miRNA, to identify genes concerned, and to 
understand whether such a mechanism could account, at least in part, for the effect of 
MSC treatment in ALS-affected mice. 
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2. Materials and Methods 
 
2.1 N9 microglia cell line culture 
The microglial cell line N9 results from the immortalization of cultures from encephalus of 
mouse embryo at the thirteenth day via retrovirus 3RV containing an activated v-myc 
oncogene. The N9 are plated in 75 cm2 cell culture flasks at a concentration of 5-6x105 in 
15 ml RPMI (Sigma-Aldrich) medium with 10% of Fetal Bovine Serum (FBS) (Lonza Cat 
No. DE14-801F), penicillin 100 U/ml, streptomycin 100 μg/ml, maintained at 37° C and 5% 
CO2 in incubator. For microglial activation, 1 μg/ml lipopolysaccharide (LPS, Sigma-
Aldrich, cat. no. L2137-5MG) was added to the culture medium for 24 hours. 
 
2.2 MSC culture 
MSC were derived from bone marrow obtained from tibia and femur of 6-8 weeks old 
female C57Bl/6J mouse. After withdrawal from the animal, tibia and femur were transferred 
to a Petri dish in which, with an insulin syringe, 1 ml of sterile medium (RPMI, Sigma-
Aldrich) was injected into the channel of each bone to eject the bone marrow content. The 
marrow fragments, deposited on the bottom of the Petri, were minced with the needle of 
the syringe. The suspension was transferred to a 15 ml Falcon tube and brought to a final 
volume of 10 ml with RPMI. Two washings were made through centrifugation at 1500 rpm 
for 5 minutes at room temperature and the obtained pellet was resuspended in 1 ml of 
MesenCult MSC Basal Medium (mouse) (Stem Cell Technologies Inc., cat. n. 05401) and 
counted in Burker's chamber. 
The cells were then plated in 75 cm2 cell culture flasks at a total concentration of 20-25x106 
in 15 ml of mouse-specific Mesencult and maintained at 37° C and 5% CO2 in incubator, 
changing MesenCult medium every 3/4 days for 4/5 weeks, time to reach about 80% of 
confluence. Cell culture were maintained in 75 cm2 flask, plating 3x105 cells and splitting 
them upon reaching confluence with a 0.05% trypsin solution containing 0,02% 
ethylenediaminotetraacetic acid (EDTA, Sigma-Aldrich). Mature cells were obtained after 
4-5 culture steps and were defined as having the ability to inhibit proliferation of 
splenocytes in vitro and their expression of stromal markers such as CD9, Sca-1, CD73 
and CD44, but not of hematopoietic markers, such as CD45, CD34 and CD11b. 
 
2.3 Primary microglia isolated from wtSOD1 or SOD1G93A mice 
Primary microglia were obtained from brain of 135-day old wtSOD1 mice (transgenic mice 
that overexpress the human SOD1 wt) or SOD1G93A (transgenic mice that overexpress 
mutated human SOD1) mice. Brains were chopped in a Petri dish and transferred into a 
 16 
 
15 ml Falcon tube with 2 ml of activated papain solution (2 ml of Papain stock solution 
(composed by 10 ml raw papain (Roche cat. no. 10108014001), 0.4 ml 0.5 M EDTA (2 mM 
final), 10 ml 10x HBSS Ca2+ and Mg2+ free (1x final), 2.5 ml 1 M HEPES (25 mM final), 
77.1 ml ddH2O) with 10 µl 14.3 mM β-Mercaptoethanol (BME)) for 30 minutes at 37° C in 
the water bath, pipetting every 10 minutes. 500 µl of leupeptin (R&D Systems, cat. 
no.EI002) were added to the suspension and mixed thorougly for 2 minutes. 8 ml 
prewarmed Dnase (Sigma, cat. no.D5025) were added to the samples and incubated for 
10 minutes at 37° C. Suspensions were filtered with a 100-250 µm filter. Samples were 
centrifuged at 450 x g at 4° C for 5 minutes. Supernatants were aspirated and the pellets 
were resuspended in 9 ml of RPMI with 25 mM Hepes with 10% FBS and 3.6 ml of 100% 
Percoll (Sigma-Aldrich cat. no.P1644-500ML) (composed of 9 parts of Percoll and 1 part 
of 10x HBSS). 1 ml of 10% FBS in RPMI was stratified over the Percoll and cell 
suspension. Samples were centrifuged at 800 x g at 4° C for 15 minutes without brake. 
Pellets were resuspended and cells were counted. After determining the cell count, 
primary microglia were purified using CD11b (Microglia) MicroBeads (Miltenyi Biotec, cat. 
no. 130-093-634), following the instructions provided. 
 
2.4 Transfection 
1X105 cells were plated in 24-well plate in 500 µl of RPMI and transfected using the 
HiPerFect® Transfection Reagent (Qiagen), according to the instruction, with mimics 
specific for each miRNA (miRNA Mimic miRNA, Qiagen) for 48 hours to analyze the ability 
of miRNA to modulate microglial phenotype, with mimics specific for each miRNA (miRNA 
Mimic miRNA, Qiagen) and with MISSION miRNA Mimic Negative Control, a synthetic 
miRNA mimic (Sigma-Aldrich cat. no. HMC0002) which does not recognize any gene 
target in cells, and for 1 hour to evaluate in which pathway miRNA could have a modulatory 
role on microglia cells. 
 
2.5 Isolation of MSC-derived exosomes 
MSCs were cultured in 75 cm2 flasks at a concentration of 5-6x105 in 15 ml of MesenCult 
MSC Basal Medium and allowed to expand. 
Before they reached confluence, MSCs were stimulated with IFN-γ at concentration of 10 
ng/ml and incubated for 24 hours. After stimulation, the cells were washed with DPBS 
(Lonza cat no. BE17-512F) 3 times, and 10 ml of RPMI 1640 medium containing 
penicillin/streptomycin and L-glutamine were added to the culture which was incubated for 
24 hours. In order to increase the production of exosomes by MSC, the cells were 
stimulated for 20 minutes with ATP (Sigma-Aldrich, cat. no A6419-1G) 1 mM at 37° C 
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(Bianco et al., 2005). Subsequently the supernatant was centrifuged at 2,000 x g at 4° C 
for 20 minutes to eliminate all cells and debris. To recover the exosomes, the supernatant 
was incubated overnight at 4° C with 0.5 volume of Total Exosome Isolation Kit (Invitrogen, 
cat. no.4478359) and centrifuged at 10,000 x g at 4° C for 1 hour. The pellet containing 
the exosomes was then resuspended in various solutions based on experimental needs. 
 
2.6 Microglia exposure to IFN-γ primed MSC-derived exosomes 
1x105 LPS-activated N9 cells or 3x105 primary microglia were plated in a 24-well plate with 
1 ml RPMI in presence or absence of exosomes derived from IFN-γ-stimulated MSC. The 
amount of exosomes put in culture was based on the number of MSC from which the 
exosomes derived, maintaining the ratio microglia:MSC = 1:3. Cells were incubated at 37° 
C and 5% CO2 for 24 hours, then processed for the extraction of RNA. 
 
2.7 RNA extraction, mRNA retrotranscription in cDNA and real time 
PCR 
RNA was isolated through the phenol-chloroform extraction procedure, using QIAzol Lysis 
Reagent (Qiagen, cat. no.79306). The purity of the RNA was evaluated by 
spectrophotometric analysis at the absorbance 230, 260 and 280 nm, to exclude the 
presence of peptides, phenols, aromatic compounds, or carbohydrates and proteins. 
The cDNA was synthesized according to the instructions provided by the kit used 
(Transcriptor First Strand cDNA synthesis kit, Roche Diagnostics, Germany). 
Quantification of the gene expression was evaluated in duplicate, in a final volume of 20 
μl containing 50 ng cDNA, 1 μl of each pair of forward and reverse primers (20 μM) 
(synthetized by Tib Molbiol) and 10 μl of FastStart Essential DNA Green Master (Roche, 
cat. no.06402712001), using the LightCycler 480 (Roche). The amplification of the 3-
phosphate dehydrogenase glyceraldehyde gene (GAPDH) was adopted as housekeeping 
gene to normalize data. 
Primer sequences used: Tnf-α forward (5′-TCTTCTCATTCCTGCTTGTGG-3′) and 
reverse (5′-GGTCTGGGCCATAGAACTGA-3′); Il1β forward (5’-
AGTTGACGGACCCCAAAAG-3′) and reverse (5′-TTTGAAGCTGGATGCTCTCAT-3′); 
Cx3cr1 forward (5′-AAGTTCCCTTCCCATCTGCT-3′) and reverse (5′ - 
CAAAATTCTCTAGATCCAGTTCAGG - 3′); Nr4a2 forward (5′-
TCAGAGCCCACGTCGATT-3′) and reverse (5′-TAGTCAGGGTTTGCCTGGAA-3′); 
Cd206 forward (5′-CCACAGCATTGAGGAGTTTG-3′) and reverse (5′-
ACAGCTCATCATTTGGCTCA-3′); Mk2 forward (5’-AGTGCAGCTCCACCTCTCTG-3’) 
and reverse (5’-CAGCAAAAATTCGCCCTAAA-3’); Map3k8 forward (5’-
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TTCCAGTGCTCATGTACTCCA-3’) and reverse (5’-GGACTGCTGAACTCTGTTTGC-3’); 
GAPDH forward (5’-ATGGTGAAGGTCGGTGTGA-3’) and reverse (5’-
AATCTCCACTTTGCCACTGC-3’). 
 
2.8 miRNA retrotranscription in cDNA, Microarray analyses and real 
time PCR 
RNA was extracted from MSC which were activated or not with IFN-γ (10 ng/ml) for 24 
hours or exosomes isolated therefrom, according to manufacturer’s instructions 
(miRNeasy Mini Kit, Qiagen, Netherlands). The purity of the RNA was evaluated by 
spectrophotometric analysis at the absorbance 230, 260 and 280 nm, to exclude the 
presence of peptides, phenols, aromatic compounds, or carbohydrates and proteins. 
Microarray analyses were performed on 5μg of RNA by LC Science LLC (Houston, TX). 
The cDNA was obtained from 200 ng of total miRNA according to manufacturer’s 
instructions (miScript II RT Kit, Qiagen, Netherlands). 
MiRNA expression was analyzed by RT-PCR using a suitable kit (miScript SYBR Green 
PCR Kit, Qiagen, cat. no. 218073) in a final volume of 25 μl containing 2.5 μl of cDNA, 2.5 
μl of the specific forward primer (10 pmol / μl) (miScript miRNA Mimic, Qiagen), 12.5 μl 
Universal Primer, and 12.5 μl Master Mix, using the LightCycler 480 (Roche). The Scarna-
17 (Qiagen, cat. no. MS00014014) miRNA amplification was used as housekeeping gene 
to normalize data. 
 
2.9 Western Blot on Exosomes 
To verify the purity of the exosomes, exosomes released by IFN-γ-stimulated MSC culture 
were lysed in RIPA buffer containing a protease inhibitors cocktail (Roche, Indianapolis, 
IN). Proteins were quantified through Pierce BCA Protein Assay kit (Thermo Fisher 
Scientific, cat. no. 23227) following provided instructions. 15 μg of proteins were loaded 
on a precast gel with polyacrylamide from 4% to 12% gradient (Life Technologies, cat. 
no.NW04120BOX), using the Bolt® Mini Gel Tank (Life Technologies) system. Protein 
were then transferred on a nitrocellulose membrane (BioRad, Hercules, CA) using XCell 
II™ Blot Module (Life Technologies). After blocking in BSA 5% in PBS + 0.1% Tween-20 
for 1 hour, the membrane was incubated overnight at 4° C with primary rabbit anti-ALIX 
(1: 1000, Merck Millipore, Milan, Italy) and anti-CD9 (1:1000, BD Pharmigen, cat. 
no.553758) antibodies in BSA 2% in PBS + 0.1% Tween-20. Membranes were washed 
three times with PBS + 0.1% Tween-20 for 5 minutes and incubated with goat anti-rabbit 
IgG secondary antibody conjugated with horseradish peroxidase (1: 5000, Merck Millipore, 
cat. no. 12-348) in BSA 2% in PBS + 0.1% Tween-20 for 1 hour. Membranes were washed 
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three times with PBS + 0.1% Tween-20 and then developed using the ECL Plus kit 
(Thermo Fisher Scientific, Rockford, IL). 
 
2.10 Electronic microscopy analyses on exosomes 
To observe the exosomes at the electronic microscope, the samples were fixed according 
to a published protocol (Théry et al., 2006). The exosomes were resuspended in a volume 
of 50-100 μl of paraformaldehyde (PFA) at 2%. 5 μl of resuspended pellet was allowed to 
adhere to electron microscopy screens (Formvar-Carbon) for 20 minutes at 42° C. 
Subsequently, the screens were washed 2 times with 100 μl of PBS for 3 minutes, after 
with 1% glutaraldehyde for 5 minutes. Finally, the screens were washed with 100 μl of 
distilled water for 2 minutes for seven times. For the contrast phase, the screens were 
transferred to 50 μl of 2% uranyl acetate (UA) solution for 5 minutes and then transferred 
to 50 μl of methylcellulose (MC) and UA (9 ml MC + 1 ml UA 4%) for 10 minutes in ice. 
Finally, the screens were dried on a filter paper and then in the air. The sections were 
visualized using a FEI CM10 microscope and acquired via a Leo912ab camera. 
 
2.11 Western Blotting of LPS-activated N9 cells transfected with 
miRNA mimics 
LPS-activated N9 transfected were lysed in RIPA buffer containing a protease inhibitor 
cocktail (Roche, Indianapolis, IN). Proteins were quantified through Pierce BCA Protein 
Assay kit (Thermo Fisher Scientific, cat. no. 23227) following manufacturer’s instructions. 
15-30 μg of proteins were loaded on precast 4% to 12% polyacrylamide gradient gels (Life 
Technologies, cat. no.NW04120BOX) and the gels were run using the Bolt® Mini Gel Tank 
(Life Technologies) system. Proteins were then transferred on a nitrocellulose membrane 
(BioRad, Hercules, CA) using XCell II™ Blot Module (Life Technologies). After blocking in 
BSA 5% in PBS + 0.1% Tween-20 for 1 hour, the membrane was incubated overnight at 
4° C with anti-phosphorylated p38 (1:2000, Cell Signaling, cat. no.4511) antibody in BSA 
2% in PBS + 0.1% Tween-20. The membrane was washed three times with PBS + 0.1% 
Tween-20 for 5 minutes and incubated with anti-IgG secondary antibody conjugated with 
horseradish peroxidase (1: 5000, Merck Millipore, Milan, cat. no. 12-348) in BSA 2% in 
PBS + 0.1% Tween-20 for 1 hour. The membrane was washed three times with PBS + 
0.1% Tween-20 and then developed using the ECL Plus kit (Thermo Fisher Scientific, 
Rockford, IL). The concentration of the phosphorylated form of p38 was normalized on the 
level of expression of total p38.  
The membrane was stripped for reprobing following the Harsh Stripping protocol (AbCAM). 
The membrane was incubated in a pre-warmed solution containing 20 ml SDS 10%, 12.5 
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ml TrisHCl pH 6.8 0.5 M, 67.5 ml ultra pure water and 0.8 ml β-mercapto-ethanol at 50° C 
for 45 minutes with some agitation. The membrane was rinsed under running water tap for 
1-2 hours and washed for 5 minutes in PBS+ 0.1% Tween-20. After blocking in BSA 5% 
in PBS + 0.1% Tween-20 for 1 hour, the membrane was incubated overnight at 4° C with 
the anti-p38 (1:2000, Cell Signaling, cat. no.9212) in BSA 2% in PBS + 0.1% Tween-20. 
The membrane was washed three times with PBS + 0.1% Tween-20 for 5 minutes and 
incubated with goat anti-rabbit IgG secondary antibody conjugated with horseradish 
peroxidase (1: 5000, Merck Millipore, Milan, Italy) in BSA 2% in PBS + 0.1% Tween-20 for 
1 hour. The membrane was washed three times with PBS + 0.1% Tween-20 and then 
developed using the ECL Plus kit (Thermo Fisher Scientific, Rockford, IL). 
 
2.13 Bioinformatics analysis of miRNA 466q and miRNA 467f 
Online softwares miRWalk, MicroT4, miRanda and Targetscan were consulted to predict 
specific target genes of miRNA 466q and miRNA 467f. Pathways in which miRNA 466q 
and 467 might have a modulation were predicted in-silico using Kyoto encyclopedia of 
genes and genomes (KEGG) Pathway database which predicts on the basis of miRNA 
sequences. In order to lower the false positive results, Panther database was consulted to 
predict pathways in which target genes identified through miRWalk are involved. 
 
2.14 Statistical analysis 
The results are represented as mean ± standard error (SEM). Statistical analysis was 
performed on independent experiments using Student's test using the Prism 5 program 
(GraphPad Software, La Jolla, CA). In all analyses, it is considered statistically significant 
p <0.05. 
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3. Results 
 
3.1 Microarray analysis shows an up-regulation of nine miRNA in 
immunosuppressive IFN-γ-stimulated MSC  
As already known from the literature, MSC can assume immunomodulatory properties in 
inflammatory conditions (Krampera et al., 2006; Sivanathan et al., 2014). In particular, IFN-
γ was shown to license the ability of MSC to acquire an immunosuppressive profile, 
inhibiting T cells proliferation and this occurs mostly through the activation of IDO that 
catalyzes the catabolism of tryptophan, essential amino acid for T cell growth (Munn et al., 
1999; Krampera et al., 2006; Meesuk et al., 2016). We have speculated that at least part 
of the immunomodulatory role of MSC on microglia could be exerted via exosome-shuttling 
of specific miRNA that affect inflammatory pathways in the target cell. To assess if the 
switch to an immunosuppressive phenotype was associated with changes in miRNA 
content in the MSC, we analyzed, through microarray (LC Sciences), the expression of 
miRNA on MSC stimulated with IFN-γ compared to unstimulated ones. We identified nine 
microRNA (listed in Table 3.1) that are significantly upregulated in IFNγ-activated MSC 
compared to their expression in unstimulated MSC, and validated their upregulation in 
immunosuppressive MSC through qRT-PCR. 
We speculated that at least some of these upregulated miRNA could be involved in the 
immunosuppressive activity of MSC. 
 
Upregulated miRNA p value 
miRNA 466i 3p p<0.05 
miRNA 669c 3p p<0.05 
miRNA 5126 p<0.05 
miRNA 466q p<0.05 
miRNA 467g p<0.05 
miRNA 467f p<0.05 
miRNA 466m 5p p<0.05 
miRNA 466i 5p p<0.05 
miRNA 3082 5p p<0.05 
 
 
 
 
Table 3.1 miRNA resulted upregulated in the 
MSC stimulated with IFN-γ (modulatory MSCs) 
compared to unstimulated MSC. p< 0.05 t test. 
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3.2 All nine miRNAs are present in MSC-derived exosomes, some 
are more abundant in immunosuppressive MSC-derived 
exosomes  
We have proposed that the suppressive mode of action of MSC could be mediated, at 
least in part, through the transfer of miRNA to target cells, via exosome shuttling. 
Accordingly, we assessed whether or not miRNA upregulated in immunosuppressive MSC 
were contained in exosomes released in the culture medium by MSC stimulated with IFN-
γ. To isolate MSC-derived exosomes, we used Total exosome isolation kit (Invitrogen), 
which permits the precipitation, and purification of exosomes from MSC supernatant. We 
characterized the isolated exosomes through electron microscopy (Figure 3.1a) and 
western blot analyses (Figure 3.1b).  Electron microscopy analysis revealed a preparation 
composed of purified nanovesicles, with a diameter ranging from 30 to 100 nm, as 
expected for exosomes. Moreover, we performed western blotting experiments on the 
isolated vesicles and we detected the expression of ALIX and CD9, which are exosomal 
markers, confirming the good yield of exosomes collected.   
To ascertain whether or not exosomes released by IFN-γ-treated MSC contain miRNA 
upregulated upon licensing of the immunosuppressive activity of the MSC, we measured 
the miRNA content in exosomes from MSC primed or not with IFN-γ through RT-PCR 
analyses (Figure 3.2).  
                                                                  
 
 
As seen in Figure 3.2, all the nine miRNA overexpressed in immunosuppressive MSC are 
present in MSC-derived exosomes, albeit at different levels. Only some of the miRNA, 
namely miR-466q, -466m 5p, -466i 3p and -467f, are significantly upregulated in exosomes 
released by IFN-γ-primed MSC. These outcomes may suggest a possible active role 
played by these specific miRNA in the immunomodulatory capacity of MSC. 
 
Figure 3.1 Characterization of exosomes isolated 
from MSC culture (a) The exosomal characterization 
was performed through electronic microscopy analyses.  
(b) The expression of the exosomal markers ALIX and 
CD9 was analyzed through western blot on lysate of 
exosomes isolated from conditioned medium of IFN-γ-
primed MSC using primary antibodies anti-ALIX and anti-
CD9.  
A   B   
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3.3 miR-466q and -467f affect the expression of pro-inflammatory 
cytokines, showing an anti-inflammatory potential 
In order to investigate whether the miRNA overexpressed in immunosuppressive MSC 
show a modulatory role in activated microglia upon transfer, our prerequisite was that 
microglial N9 cells, upon activation with LPS, did not themselves overexpress any of the 
nine selected miRNA shown to be upregulated by modulatory MSC. RT-PCR analyses 
demonstrated that there is a basal expression of miRNA in unstimulated microglia which 
does not increase when the cells are activated (Figure 3.3). 
  
Figure. 3.2 Exosomes derived from MSC primed or not with IFN-γ are differentially enriched in miRNA. miRNA 
upregulated in MSC are present in the derived exosomes, but not all at the same level and only some are significantly 
more expressed in the exosomes derived from immunomodulatory MSC. (RT-PCR analysis). *P < 0.05 
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Figure 3.3 Activated microglia N9 cells do not overexpress any of the nine miRNA upregulated in 
immunomodulatory MSC. There is no difference in the expression of the nine miRNA upregulated in immunosuppressive 
MSC in stimulated and unstimulated N9. (RT-PCR) 
 
With the purpose of understanding if miRNA upregulated in immunosuppressive MSC 
could affect the molecular phenotype of activated microglia, we used mimics (synthetically 
generated oligonucleotide of identical sequence with endogenous miRNA) of the miRNA 
upregulated in immunosuppressive MSC to transfect immortalized microglial N9 cells 
activated with a pro-inflammatory stimuli, lipopolysaccharide (LPS). Then we evaluated if 
these miRNA have an effect on the microglial profile by measuring the mRNA expression 
of TNF-α and IL-1β, as pro-inflammatory phenotype markers, and CX3CR1, as a marker 
of alternative microglia activation (Figure 3.4). As expected from our previous and other 
studies, activation with LPS induced microglia to overexpress the main pro-inflammatory 
cytokines and to downregulate CX3CR1 expression. Transfection with mimics 
demonstrated that some of the nine miRNA could regulate pro-inflammatory pathways, 
with miR-466q and -467f inducing down-regulation of TNF-α and IL-1β and miR-466m 5p 
inducing a reduced expression of IL-1β, while others (miR-5126, -466m 5p and -3082 5p) 
upregulated the expression of CX3CR1.  
Interestingly, miR-466q and -467f, which appear involved in the regulation of expression 
of inflammatory genes, were significantly overexpressed in the exosomes released by 
immunosuppressive MSC, as shown above (Figure 3.2). Results obtained suggest a 
selective role of specific miRNA in microglia phenotype modulation, in particular these two 
 25 
 
miRNA could be able to modify microglia activation state from a pro-inflammatory (M1-like) 
to an anti-inflammatory/neuroprotective (M2-like) phenotype. For this reason, we focused 
our further studies on miRNA 466q and miRNA 467f. 
 
 
 
 
 
 
 
 
3.4 miR-466q and -467f could modulate MAPK signaling pathway by 
affecting their target gene expression 
miRNA are sequences of regulatory RNA that promote, in most cases, the inhibition or 
degradation of their mRNA targets. We hypothesized that modulatory MSC induce 
alternative microglia activation through exosome-shuttling of miRNA that would affect gene 
expression by microglia cells. 
To predict possible miRNA targets, we used miRWak online database, which provides 
information on predicted miRNA target genes, calculated through algorithms based on 
different parameters, such as complementary and pairing sequences, AU content and 
binding miRNA-mRNA energy. Through miRWalk database, we predicted 241 target 
Figure 3.4 Transfection with specific miRNA mimics induces changes in molecular phenotype of activated N9 
microglia. When stimulated with LPS, N9 are activated, as demonstrated by the significant increase of the expression 
of pro-inflammatory cytokines and the significant decrease of Cx3cr1, a marker of alternative activated microglial 
phenotype. Transfection of LPS-activated N9 with synthetic mimics of the nine miRNA upregulated in modulatory MSC 
demonstrates the effect of miR-466q and miR-467f that significantly reduce the expression of TNF and IL1b (pro-
inflammatory markers), whereas miR-466m 5p, miR-5126 and miR-3082 5p affect the mRNA expression of Cx3cr1 
(“neuroprotective” marker). (RT-PCR analysis). (None vs LPS-activated N9) ## P< 0.01; ### P< 0.001; (LPS-activated N9 
vs transfected LPS-activated N9) *P < 0.05; **P < 0.01; ***P<0.001 
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genes of miR-466q and 494 target genes for miR-467f. To better understand the role of 
miRNA in the modulation of microglia activation, we analyzed in-silico pathways in which 
target genes of miR-466q and -467f could be involved. We used two different parameters 
to predict pathways modulated by miRNA 466q and 467f. We used the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) database, which predicts pathways based on miRNA 
itself, and Panther Classification System, which predicts pathways on the basis of 
predicted target genes we identified through miRWalk database. By combining data from 
these two databases, we predicted a number of pathways, listed in Table 3.2a, which 
specific miRNA might modulate. Of these, we have chosen to focus on the MAPK signaling 
pathway, which could be regulated by both miR-466q and miR-467f, because it plays an 
important role in inflammatory cytokine expression. Accordingly, the miRNA could play an 
anti-inflammatory role in activated microglia by preventing the activation of MAPK pathway 
via inhibition of the expression of some of its component.  
 
    
 
 
 
  
 
 
 
 
 
 
 
 
 
miR-467f 
Pathways in cancer Dorso ventral axis formation 
TGF beta signaling pathway Adipocytokine signaling pathway 
Endometrial cancer Vascular smooth muscle 
contraction 
Acute myeloid leukemia Wnt signaling pathway 
Chronic myeloid leukemia Regulation of actin cytoskeleton 
Colorectal cancer Ubiquitin mediated proteolysis 
MAPK signaling pathway Melanoma 
B cell receptor signaling pathway Glioma 
ErbB signaling pathway Gap junction 
Prostate cancer Basal cell carcinoma 
Renal cell carcinoma Fc epsilon RI signaling pathway 
Chemokine signaling pathway Jak STAT signaling pathway 
T cell receptor signaling pathway GnRH signaling pathway 
Sphingolipid metabolism  
miR-466q 
Pathways in cancer 
Neurotrophin signaling 
pathway 
Colorectal cancer 
Endometrial cancer 
Amyotrophic lateral 
sclerosis ALS 
MAPK signaling 
pathway 
Thyroid cancer 
VEGF signaling 
pathway 
Fc epsilon RI signaling 
pathway 
MAPK signaling pathway 
Target of miR-466q Target of miR-467f 
MAPK11/p38beta Eif4ebp1 
MAPKAPK1c MAPKAPK3/MK3 
MAPKAPK2/MK2 IL1R type 1 
 MAPK3/ERK1 
 MAP3K8 
Table 3.2 miR-466q and -467f might have a role in the 
modulation of MAPK signaling pathway through affecting 
their target genes 
(a) Bioinformatic analysis predicted regulation of MAPK 
pathway by miR-466q and miR-467f. (b) Bioinformatic 
analysis predicted target genes of  miR-466q and miR-467f 
whithin the MAPK signaling pathway. 
A 
B 
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To further understand the possible effect of miR-466q and -467f on MAPK signaling, we 
analyzed their predicted target genes that are components of this pathway. Of the several 
components of MAPK pathway which could be regulated by miRNA-466q and -467f (Table 
3.2b), we focused on MAPKAPK2 (or MK2), target of miR-466q, and MAP3K8, target of 
miR-467f, important steps of activation of the p38 pathway (Figure 3.5), which plays a key 
role in neuroinflammation. In addition, an overactivation of the p38 MAPK signaling 
pathway has also been observed in degenerating MN and reactive astrocytes in ALS 
patients (Bendotti et al., 2004) and in post-mortem human ALS brain tissues (Sama et al., 
2017). For its implications in ALS pathology, we decided to further analyze the effect of 
the immunomodulatory miRNA on this pathway.  
 
 
 
 
 
To validate whether MK2 and MAP3K8 are really targets of miR-466q and -467f in 
microglia, we performed RT-PCR for MK2 and MAP3K8 mRNA on LPS-activated N9 and 
transfected with the relevant mimics. When stimulated with LPS, the cells show an 
upregulation of both these genes. As we expected, miR-466q induced a downregulation 
of its direct target, Mk2, affected also by miR-467f, whose upstream effect on its target, 
Map3k8, affects the whole pathway. Interestingly, the expression of Map3k8 was inhibited 
by both miRNA, in particular miR-467f inhibits its translation by directly targeting it, while 
miR-466q apparently does this through an indirect mechanism still unknown. Our results 
validated that miR-466q and -467f modulate the expression of these two genes involved 
in the p38 MAPK pathway (Figure 3.6). 
Figure 3.5 p38 MAPK signaling might be modulated by 
miR-466q and -467f. In the p38 pathway, miR 467f targets 
MAP3K8 and 466q targets MK2. The effect of both miRNAs 
on their targets affects the phosphorylation of p38. 
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3.5 miR-466q and -467f affect the p38 MAPK pathway  
To evaluate how miRNA modulation affects the p38 MAPK signaling pathway, we 
assessed phosphorylation of p38 compared to the total p38 expressed through WB 
analyses of LPS-activated N9 cells transfected with mimics of miR-466q and -467f. We 
observed an expected increase in the phosphorylated form of this situation. This effect 
could be specifically attributed to these miRNA, as transfection with a negative control (a 
synthetic miRNA mimic (Sigma-Aldrich) which does not recognize any gene target in cells) 
did not have any effect (Figure 3.7). 
 
 
 
 
Figure 3.6 RT-PCR analysis on transfected LPS-activated N9 confirmed that Mk2 and 
Map3k8 are target genes of miRNAs 466q and 467f. *P<0.05; **P<0.01; ***P<0.001 
 
 
Figure 3.7 miR-466q and -467f are able to affect the phosphorylation of p38, inhibiting the activation 
of p38 MAPK pathway Transfection of LPS-stimulated N9 with mimics of miRNA 466q and miRNA 467f 
decreases p38 phosphorylation. (Western Blot).  
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3.6 Exosomes derived from IFN-γ-primed MSC affect genes related 
to the inflammatory and neuroprotective phenotype of microglia 
We had demonstrated that the exosomes released by immunomodulatory MSC contain 
miRNA upregulated in IFN-γ-primed MSC. We had observed that these specific miRNA 
have an effect on the molecular phenotype of activated microglia, and in particular miR-
466q and -467f that are significantly more abundant in the immunomodulatory MSC-
derived exosomes compared to exosomes released by unstimulated MSC, and have an 
anti-inflammatory role. To have the proof of concept that the immunosuppressive MSC-
derived exosomes, containing modulatory miRNA, can mediate the paracrine effect of 
MSC on activated microglia, we exposed LPS-activated N9 cells to the IFN-γ-primed MSC-
derived exosomes. Results obtained confirmed the role of exosomes in mediating the 
immunomodulatory effect of MSC on the molecular phenotype of activated microglia. 
Indeed, N9 cell activation to a pro-inflammatory profile, as demonstrated by the 
overexpression of Tnf and downregulation of the expression of alternative activated 
microglia phenotype marker, was reverted upon exposure to IFN-γ-primed MSC-derived 
exosomes, with downregulation of TNF expression and upregulation of the expression of 
markers of alternative microglial activation, Cx3cr1 and Nr4a2 (Figure 3.8). 
 
 
 
 
 
Figure 3.8 Exosomes derived from immunosuppressive MSC are able to affect the molecular 
phenotype of activated microglia. Exposure to exosomes derived from modulatory MSC results in 
downregulation of the pro-inflammatory gene (Tnf) and upregulation of genes associated with anti-
inflammatory/neuroprotective phenotype (Cx3cr1 and Nr4a2) in LPS-activated immortalized  microglial 
cell line. (RT-PCR analysis). *P < 0.05; ***P<0.001 
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3.7 Immunosuppressive MSC-derived exosomes affect the 
molecular phenotype of end-stage mSOD1-microglia 
We have postulated that the beneficial effect of MSC in the murine ALS model could be 
mediated, at least in part, by exosome shuttling of specific miRNA inducing a shift of 
microglia profile from classical to alternative activation with upregulation of the 
neuroprotective phenotype. To evaluate whether the exosomes released by 
immunosuppressive MSC were able to affect the activation of microglia of SOD1G93A mice, 
we exposed primary microglia isolated from mice at the end stage of ALS, which show an 
over-activated molecular phenotype (Figure 3.9), to exosomes derived from 
immunosuppressive MSC.  
 
 
 
 
 
As can be seen in Figure 3.10, exposure of SOD1G93A microglia to IFN-γ-primed MSC-
derived exosomes led to downregulation of TNF and upregulation of M2-like molecular 
phenotype markers (Figure 3.10).  
Figure 3.9 mSOD1-microglia show an over-activated molecular phenotype at the end-stage of ALS. 
mSOD1-microglia show up-regulation of genes associated with a proinflammatory (Tnf and Il1b) phenotype and 
down-regulation of genes associated with an anti-inflammatory/neuroprotective phenotype (Cx3cr1, Nr4a2 and 
Cd206) at the end stage of disease (day 135). (q-RT-PCR analysis) *P < 0.05, **P < 0.01. 
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These data suggest that specific miRNA shuttled by exosomes derived from 
modulatory MSC are able to alter microglial gene expression, inducing a switch from 
neurotoxic to neuroprotective phenotype, and that this occurs, at least in part, through 
the regulation of p38 MAPK signaling pathway involved in the expression of 
inflammatory mediators.  
  
Figure 3.10 Exposure to exosomes derived from modulatory MSCs results in downregulation of the pro-
inflammatory gene (Tnf) and upregulation of genes associated with anti-inflammatory/neuroprotective phenotype 
(Cx3cr1 and Nr4a2) in microglia isolated from end-stage mSOD1 mice. (RT-PCR analysis). 
*P < 0.05 
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4. Discussion and conclusion 
The microglia act as guardians of brain homeostasis until they perceive an activating signal 
(Amor, 2010). In most cases, immune responses in the CNS lead to repair and 
regeneration (Neumann et al., 2009), but there is a delicate balance between pathogenic 
and restoring process, which can be triggered by immune responses. Modulation of 
microglia activation from the M1-like phenotype to the M2-like one represents a therapeutic 
target in research on neurological diseases characterized by a strong inflammatory 
component.  
While research aimed at modulating neuroinfiammation with classical immunomodulatory 
factors were not convincing, stem cell therapy, particularly the administration of MSC, 
which showed a potent neuroprotective, modulatory and probably also neurogenic 
potential in vitro (Zappia et al., 2005), is getting more and more considered as an 
alternative approach for treatment of neurodegenerative diseases in which the 
inflammatory component plays a key role. 
Using MSC could be a logical solution, since, in addition to carrying out an important 
immunomodulatory function, they are able to migrate where they can support local 
neurogenesis, providing support for precursors, e.g. neural stem cells, to differentiate 
(Uccelli et al., 2008). 
The use of bone marrow-derived MSC has several advantages over conventional neural, 
embryonic and hematopoietic stem cells: they can be obtained from adult bone marrow, 
are easily cultured and expandable in vitro, can be administered in an autologous manner 
without using immunosuppressive anti-rejection drugs, and lastly are apparently not 
subject to genetic change despite repeated culture steps, thus possessing a low level of 
risk of tumorigenesis compared to other types of stem cells (Kassis et al., 2008). But the 
therapeutic effectiveness of MSC depends on their ability to modify the damaged tissue 
microenvironment. These events take place through the release of inflammatory cytokines, 
anti-apoptotic molecules and neurotrophic factors that promote repair and protection of 
damaged tissues (Uccelli et al., 2008). 
In this work, we demonstrated the presence of specific miRNA in exosomes derived from 
immunomodulatory MSC, which are able to influence the activated molecular phenotype 
of microglia in vitro, leading them to acquire an alternative activated phenotype 
characterized by the expression of anti-inflammatory / neuroprotective molecules. We 
observed that in inflammatory conditions, simulated in our in vitro experiments by 
stimulation with IFN-γ, MSC showed a different expression of endogenous miRNA, 
compared to MSC at basal conditions, and in particular we evidenced the significant over-
expression of nine specific miRNA. This interesting aspect suggests that at least some of 
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the nine overexpressed miRNA in the MSC could be involved in the immunosuppressive 
activity of the IFN-γ-primed MSC, through modulation of gene expression in target cells 
(Krampera et al., 2005; Sivanathan et al., 2014; Rasmusson et al., 2003).  
Our aim was to investigate whether specific miRNA-shuttled by exosomes derived from 
immunomodulatory MSC could account for the modulatory paracrine action of these MSC 
on microglial cells. We confirmed the presence of all the nine miRNA in the exosomes 
released by IFN-γ-treated MSC. Of interest, we observed a differential enrichment of 
specific miRNA in the exosomes derived from immunosuppressive MSC compared to the 
parental cells, with some of the miRNA being present in significantly greater amount in the 
exosomes derived from modulatory MSC, thus supporting the demonstration of Squadrito 
et al. that the exosomal content does not reflect the cytoplasm of the cell from which they 
originate, but miRNA are sorted into the exosomes depending on the state of the cells 
(Squadrito et al., 2014). Accordingly, exosomes could mediate the paracrine action of MSC 
by transferring specific miRNA, that might have a role in the target cells.  
The data obtained in vitro with immortalized N9 microglial cells support the idea that MSC 
can also exert their neuroprotective effects on microglia. In addition to our previous study 
indicating that exposure of microglia to MSC significantly increases the production of 
molecules potentially involved in anti-inflammatory / neuroprotective mechanisms (Giunti 
et al., 2012), we show here that MSC are also able to inhibit microglia activation and the 
production of inflammatory mediators. Transfection of selective miRNA in activated 
microglia showed that some miRNA are able to affect microglia activation, inhibiting the 
expression of pro-inflammatory cytokines or upregulating the expression of M2-like 
marker. Interestingly, we noted correlations between the “beneficial” anti-inflammatory 
effect displayed by some modulatory miRNA when transferred to activated microglia 
through transfection of mimics or through exosome shuttling, in particular miR-466q and -
467f, and their significant over-expression in the exosomes derived from 
immunomodulatory MSC. Indeed, it is well known that exosomes are modulators of 
neuroinflammation (Gupta and Pulliam, 2014) by shuttling soluble factors, mRNA and 
miRNA. In particular, we proposed that these two miRNA can attenuate M1-like microglia 
functions acting on the p38 MAPK pathway, which is involved in the neuroinflammation 
process. Many groups (Morfini et al., 2013; Holasek et al., 2005; Lee et al., 2013; Tortarolo 
et al., 2003; Nahirnyj et al., 2013; Lee and Kim, 2017; Sama et al., 2017; Bendotti et al., 
2004) have reported the increase of activation of p38 MAPK both in SOD1G93A mice and 
in human sporadic and familial ALS cases (Bendotti et al., 2004; Picher-Martel et al., 
2015), suggesting the crucial role of this pathway in ALS pathology. In this context, the 
possible inhibitory role of p38 MAPK signaling pathway played by miR-466q and -467f 
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could be of relevant importance for all pathology in which there is an inflammatory 
component, including ALS.   
On the basis of results obtained in vitro, we aimed at demonstrating the effect of 
modulatory miRNA in controlling microglial activation in the animal model of ALS. 
Although microglia assume a neuroprotective phenotype at the clinical onset of murine 
ALS, they switch to a proinflammatory phenotype towards the end stage of pathology 
(Zhao et al., 2013); accordingly, we analyzed the clinical stage of the disease in the 
SOD1G93A mice in which the primary microglia assume an over-activated and more 
deleterious phenotype. Our results on primary microglia reflect the modulatory effect of 
exosomes obtained in vitro, indeed we observed a reduction in microglia activation. 
Although exosome functions are still not well defined, it is clear that they play an important 
role in intercellular communication and our results confirmed that exosomes can mediate 
paracrine effects exerted by MSC on microglia cells, and that their content can modulate 
microglia activation. The usefulness of exosomes depends on their ability to cross the 
blood-brain barrier (BBB), highly impenetrable to most drugs, and their potential as a 
therapeutic vehicle in inflammatory neurological disorders has been demonstrated in vivo 
with intra-nasal administration in the animal model of the EAE (Zhuang et al., 2011). The 
importance of the exosomes as a therapeutic tool also includes their capacity to reach 
specific tissues and deliver their cargo into particular cells, in which they have to act 
(Bryniarski et al., 2013). 
The therapeutical use of exosomes would provide several advantages compared to 
classical cell therapy, mainly linked to the ability to mitigate risks associated with cell 
transplantation and the ability to transport soluble factors, transcription factors, genes and 
miRNA (Lai et al., 2011; Andaloussi et al., 2013). 
The results obtained from this study support the starting experimental hypothesis, that 
MSC can exert their modulatory effect on activated microglia by the transfer of specific 
miRNAs contained in their exosomes. 
We are planning to perform pre-clinical studies in SOD1G93A mice to verify the efficacy of 
MSC-derived exosomes administered intra-nasally, a route that has been demonstrated 
to be the preferential exosomal route to efficiently reach the neural tissue and deliver their 
cargo in microglia cells (Zhuang et al., 2011). 
Overall, this study will provide us important information about the innovative use of miRNA 
derived from MSC as a therapeutic tool for controlling neuroinflammation not only in ALS 
but also in other neurodegenerative diseases in which neuroinfiammation plays a 
fundamental role in the disease progression. 
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